Karin Gehring1, Martin J B Taphoorn1, Margriet M Sitskoorn1, Neil K Aaronson1. 1. Tilburg University, Department of Cognitive Neuropsychology , Tilburg , The Netherlands (K.G., M.M.S.); Medical Center Haaglanden, Department of Neurology , The Hague , The Netherlands (M.J.B.T.); VU University Medical Center, Department of Neurology , Amsterdam, The Netherlands (M.J.B.T.); The Netherlands Cancer Institute, Division of Psychosocial Research and Epidemiology , Amsterdam , The Netherlands (N.K.A.); Programme Group Clinical Psychology , University of Amsterdam , Amsterdam , The Netherlands (N.K.A.).
Abstract
BACKGROUND: Studies in cancer and noncancer populations demonstrate lower than expected correlations between subjective cognitive symptoms and cognitive functioning as determined by standardized neuropsychological tests. This paper systematically examines the association between subjective and objective cognitive functioning in patients with low-grade glioma and the associations of these indicators of cognitive function with clusters of sociodemographic, clinical, and self-reported physical and mental health factors. METHODS: Multiple regression analyses with the subjective and 2 objective indicators of cognitive functioning as dependent variables and 4 clusters of predictor variables were conducted in 169 patients with predominantly low-grade glioma. RESULTS: Correlations between the subjective and the 2 objective cognitive indicators were negligible (0.04) to low (0.24). Objective cognitive deficits were predominantly associated with sociodemographic (older age, lower education, male sex) and clinical (left hemisphere tumor) variables, while lower ratings of subjective cognitive function were more closely related to self-reported mental health symptoms (fatigue, lower mental well-being), physical (motor) dysfunction and female sex. Self-reported communication deficits were associated significantly with both subjective and objective dysfunction. CONCLUSIONS: We recommend that both subjective and objective measures of cognitive functioning, together with a measure of psychological distress, be used for comprehensive neuropsychological assessments of patients with glioma to determine which areas are most affected and which specific intervention strategies are most appropriate.
BACKGROUND: Studies in cancer and noncancer populations demonstrate lower than expected correlations between subjective cognitive symptoms and cognitive functioning as determined by standardized neuropsychological tests. This paper systematically examines the association between subjective and objective cognitive functioning in patients with low-grade glioma and the associations of these indicators of cognitive function with clusters of sociodemographic, clinical, and self-reported physical and mental health factors. METHODS: Multiple regression analyses with the subjective and 2 objective indicators of cognitive functioning as dependent variables and 4 clusters of predictor variables were conducted in 169 patients with predominantly low-grade glioma. RESULTS: Correlations between the subjective and the 2 objective cognitive indicators were negligible (0.04) to low (0.24). Objective cognitive deficits were predominantly associated with sociodemographic (older age, lower education, male sex) and clinical (left hemisphere tumor) variables, while lower ratings of subjective cognitive function were more closely related to self-reported mental health symptoms (fatigue, lower mental well-being), physical (motor) dysfunction and female sex. Self-reported communication deficits were associated significantly with both subjective and objective dysfunction. CONCLUSIONS: We recommend that both subjective and objective measures of cognitive functioning, together with a measure of psychological distress, be used for comprehensive neuropsychological assessments of patients with glioma to determine which areas are most affected and which specific intervention strategies are most appropriate.
Authors: N K Aaronson; M Muller; P D Cohen; M L Essink-Bot; M Fekkes; R Sanderman; M A Sprangers; A te Velde; E Verrips Journal: J Clin Epidemiol Date: 1998-11 Impact factor: 6.437
Authors: M Klein; J J Heimans; N K Aaronson; H M van der Ploeg; J Grit; M Muller; T J Postma; J J Mooij; R H Boerman; G N Beute; G J Ossenkoppele; G W van Imhoff; A W Dekker; J Jolles; B J Slotman; H Struikmans; M J B Taphoorn Journal: Lancet Date: 2002-11-02 Impact factor: 79.321
Authors: Marco Ronald Hassler; Katarzyna Elandt; Matthias Preusser; Johann Lehrner; Petra Binder; Karin Dieckmann; Andrea Rottenfusser; Christine Marosi Journal: J Neurooncol Date: 2009-09-10 Impact factor: 4.130
Authors: Hanneke E Hulst; Karin Gehring; Bernard Mj Uitdehaag; Leo H Visser; Chris H Polman; Frederik Barkhof; Margriet M Sitskoorn; Jeroen Jg Geurts Journal: Mult Scler Date: 2013-11-25 Impact factor: 6.312
Authors: Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Chelsea Nicol; Tamara Ownsworth; Lee Cubis; William Nguyen; Matthew Foote; Mark B Pinkham Journal: J Cancer Surviv Date: 2019-07-17 Impact factor: 4.442
Authors: Julia Day; David C Gillespie; Alasdair G Rooney; Helen J Bulbeck; Karolis Zienius; Florien Boele; Robin Grant Journal: Curr Treat Options Neurol Date: 2016-05 Impact factor: 3.598
Authors: Isabel K Gosselt; Vera P M Scheepers; Lauriane A Spreij; Johanna M A Visser-Meily; Tanja C W Nijboer Journal: Neurooncol Pract Date: 2020-11-21
Authors: Pim B van der Meer; Johan A F Koekkoek; Martin J van den Bent; Linda Dirven; Martin J B Taphoorn Journal: J Neurooncol Date: 2021-04-06 Impact factor: 4.130
Authors: Hugo Câmara-Costa; Kim S Bull; Colin Kennedy; Andreas Wiener; Gabriele Calaminus; Anika Resch; Virginie Kieffer; Clémence Lalande; Geraldina Poggi; Katja von Hoff; Jacques Grill; François Doz; Stefan Rutkowski; Maura Massimino; Rolf-Dieter Kortmann; Birgitta Lannering; Georges Dellatolas; Mathilde Chevignard Journal: Neurooncol Pract Date: 2017-02-10
Authors: Simone Oerlemans; Sanne B Schagen; Corina J van den Hurk; Olga Husson; Dounya Schoormans; Lonneke V van de Poll-Franse Journal: J Cancer Surviv Date: 2021-03-17 Impact factor: 4.442